ArticleACS nano2023
Open access · greenAbstract read
In one paragraph
Article in ACS nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models.Cancer immunology research · 2026Article
- Radiopaque microsphere-hydrogel composite for extended-release intratumoral immunotherapy in a large animal model.Drug delivery and translational research · 2026Article
- Targeted immunomodulation for chronic diseases through advanced delivery platforms.Expert opinion on drug delivery · 2026Review
- Exosomal immune decoy integrates cfDNA scavenging and mTOR inhibition for synergistic lupus nephritis therapy.Theranostics · 2026Article
- Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models.Science advances · 2025Article
- Engineered iron oxide nanoplatforms: reprogramming immunosuppressive niches for precision cancer theranostics.Molecular cancer · 2025Review
- Tumor-Adhesive Chitosan-Derived Multi-Immune Agonist Unleashes Strong and Durable Anti-Cancer Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Review
- Intratumoral Injectable Redox-Responsive Immune Niche Improves the Abscopal Effect in Radiotherapy.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Molecular mechanisms underlying the abscopal effect induced by radiotherapy and its synergistic translational potential with immunotherapy.Therapeutic advances in medical oncology · 2025Review
- Immunogenic cell death: A new strategy to enhancing cancer immunotherapy.Human vaccines & immunotherapeutics · 2024Review
- A novel nanomedicine integrating ferroptosis and photothermal therapy, well-suitable for PD-L1-mediated immune checkpoint blockade.Materials today. Bio · 2024Review
- Bioinspired intratumoral infusion port catheter improves local drug delivery in the liver.Scientific reports · 2024Article
- Modulation of Dendritic Cell Function via Nanoparticle-Induced Cytosolic Calcium Changes.ACS nano · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Ying ZhangDepartment of Biomedical Engineering and Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, Wisconsin 53715, United States.
Md Mahfuzur RahmanDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Paul A ClarkDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Raghava N SriramaneniDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Thomas HavighurstDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin 53792, United States.
Caroline P KerrDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Min ZhuDepartment of Biomedical Engineering and Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, Wisconsin 53715, United States.ORCID 0000-0002-5832-8469
Jamie JonesDepartment of Biomedical Engineering and Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, Wisconsin 53715, United States.
Xiuxiu WangDepartment of Biomedical Engineering and Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, Wisconsin 53715, United States.ORCID 0000-0003-2480-8234
KyungMann KimDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin 53792, United States.
Shaoqin GongDepartment of Biomedical Engineering and Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, Wisconsin 53715, United States.ORCID 0000-0001-9447-2938
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.ORCID 0000-0001-5558-3547
University of Wisconsin–Madison · US
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6MRadionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BEDNARZ, BRYAN PATRICK · 2020 to 2024
$12.5MIntegrated Training For Physician-ScientistsT32GM140935 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anna Huttenlocher, Jeniel E Nett · 2021 to 2026
$6.5MImmunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0MCombining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor VaccinationDP5OD024576 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT · 2017 to 2021
$1.9MTargeted radionuclide therapy for tumor immunomodulation and enhancing immunotherapy responseF30CA268780 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KERR, CAROLINE PAULA ANNE · 2022 to 2025
$145kNCI NIH HHS F30 CA268780NCI NIH HHS P01 CA250972NCI NIH HHS P30 CA014520NCI NIH HHS U01 CA233102NIGMS NIH HHS T32 GM140935NIH HHS DP5 OD024576
Abstract
The
Indexed as
NanoparticlesNeoplasmsAnimalsAntibodiesCD8-Positive T-LymphocytesCell Line, TumorFerric CompoundsHumansInjections, IntralesionalInterleukin-2MicePolylysineTumor MicroenvironmentVaccinationAntibodiesFerric Compoundsferric oxideInterleukin-2Polylysineabscopal effectscancer immunotherapyin situ vaccinenanoparticleradiation therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.